Mark Bachleda
Nessuna posizione attualmente
Patrimonio netto: 1 540 $ in data 31/03/2024
Profilo
Mark J.
Bachleda worked as a Vice President at Bristol Myers Squibb Co. and as a Vice President-Sales & Account Management at Juno Therapeutics, Inc. He also worked as a Chief Commercial Officer at Galera Therapeutics, Inc. from 2021 to 2023.
Bachleda holds an MBA from the University of California, Berkeley and a doctorate from the University of Illinois.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 21/04/2023 | 11 000 ( 0.02% ) | 1 540 $ | 31/03/2024 |
Precedenti posizioni note di Mark Bachleda
| Società | Posizione | Fine |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 09/08/2023 |
| JUNO THERAPEUTICS INC | Sales & Marketing | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formazione di Mark Bachleda
| University of California, Berkeley | Masters Business Admin |
| University of Illinois | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GALERA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Mark Bachleda
